静止性促肾上腺皮质激素细胞腺瘤的诊断及研究进展

Diagnosis and research progress of silent corticotroph adenoma

随着生物标志物数量的急剧增加,通过术后病理组织中转录因子水平的检测可有效对垂体腺瘤行进一步划分,为医生术后治疗方案的决策、高风险腺瘤患者的管理和监测提供更准确的指导建议。其中,静止性促肾上腺皮质激素细胞腺瘤(SCA)临床上既无生化检验提示外周血激素水平的升高,同时无皮质醇增多症的临床表现,明确诊断是通过促肾上腺素病理染色证实。随着转录因子t-Pit免疫组化的引入使得SCA的诊断得到了进一步扩充,本文对目前SCA的最新诊断标准及相应研究进展进行综述。

With the rapid increase in the number of biomarkers, the detection of transcription factor levels in postoperative pathological tissues can effectively further divide pituitary adenomas, and provide more accurate guidance and suggestions for doctors’ decision-making of postoperative treatment plan and the management and monitoring of patients with high-risk adenomas. Silent corticotroph adenoma(SCA) has no biochemical test to indicate the increase of peripheral blood hormone level, and there is no clinical manifestation of hypercortisolism. The clear diagnosis is confirmed by adrenocorticotropic pathological staining. With the introduction of t-Pit immunohistochemistry, the diagnosis of SCA has been further expanded. This paper reviews the latest diagnostic criteria and corresponding research progress of SCA.